Dataset Information

A Systematic Literature Review of Brain Neurostimulation Therapies for the Treatment of Pain.

ABSTRACT:

Objective

To conduct a systematic literature review of brain neurostimulation for pain.

Design

Grade the evidence for deep brain neurostimulation (DBS).

Methods

An international, interdisciplinary work group conducted a literature search for brain stimulation. Abstracts were reviewed to select studies for grading. Randomized controlled trials (RCTs) meeting inclusion/exclusion criteria were graded by two independent reviewers. General inclusion criteria were prospective trials (RCTs and observational) that were not part of a larger or previously reported group. Excluded studies were retrospective or existed only as abstracts. Studies were graded using the modified Interventional Pain Management Techniques-Quality Appraisal of Reliability and Risk of Bias Assessment, the Cochrane Collaborations Risk of Bias assessment, and the United States Preventative Services Task Force level-of-evidence criteria.

Results

Two high-quality RCTs and three observational trials supported DBS, resulting in Level II (moderate) evidence.

Conclusion

Moderate evidence supports DBS to treat chronic pain. Additional Level I RCTs are needed to further the strength of the evidence in this important area of medicine, but the current evidence suggests that DBS should be considered as an option in treating complex pain cases.

SUBMITTER: Deer TR

PROVIDER: S-EPMC7820362 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

A Systematic Literature Review of Brain Neurostimulation Therapies for the Treatment of Pain.

Deer Timothy R TR Falowski Steven S Arle Jeff E JE Vesper Jan J Pilitsis Julie J Slavin Konstantin V KV Hancu Maria M Grider Jay S JS Mogilner Alon Y AY

Pain medicine (Malden, Mass.) 20201101 7

<h4>Objective</h4>To conduct a systematic literature review of brain neurostimulation for pain.<h4>Design</h4>Grade the evidence for deep brain neurostimulation (DBS).<h4>Methods</h4>An international, interdisciplinary work group conducted a literature search for brain stimulation. Abstracts were reviewed to select studies for grading. Randomized controlled trials (RCTs) meeting inclusion/exclusion criteria were graded by two independent reviewers. General inclusion criteria were prospective tri ...[more]

PMID: 32034418

Similar Datasets

Project description:IntroductionNumerous therapeutic agents specifically targeting the mesenchymal-epithelial transition (MET) oncogene are being developed.ObjectiveThe aim of the current review was to systematically identify and analyze clinical trials that have evaluated MET inhibitors in various cancer types and to provide an overview of their clinical outcomes.MethodsAn electronic literature search was carried out in the PubMed and Embase databases to identify published clinical trials related to MET inhibitors. The PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement was followed for the systematic appraisal of the literature. Data related to clinical outcomes, including progression-free survival, overall survival, objective response rate, and overall tumor response, were extracted.ResultsIn total, 49 publications were included. Among these, 51.02% were phase II studies, 14.28% were randomized controlled trials, three were phase III studies, two were prospective observational studies, and the remainder were either phase I or Ib studies. The majority (44.89%) of articles reported the clinical outcomes of MET inhibitors, including small molecules, monoclonal antibodies, and other agents, in patients with non-small-cell lung cancer (NSCLC) harboring MET alterations. MET amplification, overexpression, and MET exon 14 skipping mutations were the major MET alteration types reported across the included studies. Clinical responses/outcomes varied considerably.ConclusionThis systematic literature review provides an overview of the literature available in Embase and PubMed regarding MET-targeted therapies. MET-selective tyrosine kinase inhibitors (TKIs) (capmatinib, tepotinib, and savolitinib) may become a new standard of care in NSCLC, specifically with MET exon 14 skipping mutations. A combination of MET TKIs with epidermal growth factor receptor (EGFR) TKIs (osimertinib + savolitinib, tepotinib + gefitinib) may be a potential solution for MET-driven EGFR TKI resistance. Further, MET alteration (MET amplification/overexpression) may be an actionable target in gastric cancer and papillary renal cell carcinoma.

Dataset Information

A Systematic Literature Review of Brain Neurostimulation Therapies for the Treatment of Pain.

Objective

Design

Methods

Results

Conclusion

Publications

A Systematic Literature Review of Brain Neurostimulation Therapies for the Treatment of Pain.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets